Drug and Alcohol Testing

Drug and Alcohol Testing

August 09, 2024

The landscape of cannabis regulation in the United States is on the verge of a significant transformation. In May 2024, the Attorney General published a Notice of Proposed Rulemaking (NPRM) that could see marijuana reclassified from a Schedule I to a Schedule III substance under the Controlled Substances Act (CSA). This proposed change follows directives from President Biden and recommendations from the Department of Health and Human Services (HHS). In a recent webinar, Faye Caldwell, Attorney at Law at Caldwell Everson PLLC, discussed the changes. Here's what you need to know.

Drug and Alcohol Testing

July 29, 2024

The rise of fentanyl abuse poses significant challenges to workplace safety and productivity. Addressing these challenges requires comprehensive understanding and proactive measures. In a recent webinar, Lance Presley, an expert from Labcorp, discussed the impact of fentanyl on the workplace and the critical steps employers should take to mitigate its risks. Here's what you need to know.

Drug and Alcohol Testing

July 22, 2024

New guidance from the Office of Drug and Alcohol Policy and Compliance (ODAPC) on behalf of each DOT Agency has been issued, impacting the process for converting federally regulated drug tests to non-regulated status. Below, we detail these updated procedures and their implications for our clients and Medical Review Officers (MROs).

Drug and Alcohol Testing

June 13, 2024

Minnesota recently adjusted its mandatory drug, alcohol, and cannabis testing law to permit employers to perform oral fluid testing that is exempt from the state’s laboratory testing requirements. Though the updates do not specifically use the words “rapid result” or “onsite”, it clearly states that oral fluid can be used for non-laboratory testing and results must be given at the time a test occurs, making it clear that it is referring to POCT oral fluid. Oral fluid tests complying with the regulatory updates will be permitted as of August 1, 2024, for drug, alcohol, and cannabis testing purposes.

Drug and Alcohol Testing

May 15, 2024

DISA Global Solutions was recently featured in an article from NETA World’s Spring 2024 Journal, the quarterly journal published by the InterNational Electrical Testing Association (NETA). We have republished it below with permission from NETA World. Visit www.netaworld.org for more information.

Drug and Alcohol Testing

May 13, 2024

In an era where the normalization of marijuana contrasts starkly with the escalating crisis of fentanyl abuse, employers face an unprecedented challenge in maintaining safe and compliant workplaces. It’s essential HR professionals understand the evolving dynamics of workplace drug testing, between the legalization of marijuana and the alarming rise of fentanyl.

Drug and Alcohol Testing

May 07, 2024

As we observe National Fentanyl Awareness Day, it's vital to acknowledge the severe implications of the fentanyl crisis on both communities and workplaces. Fentanyl, a synthetic opioid vastly more potent than morphine, is a primary contributor to the opioid epidemic due to its clandestine addition to street drugs.